Thirona’s artery-vein and segment segmentation helps in lung cancer surgeries

A new paper has just been published in high-impact journal JTCVS Techniques, showing the added value of AI-based lung segmentation and VR technology in lung cancer surgery planning. In the study from Erasmus Medical Center, Thirona's lung CT segmentation was visualized in a 3D virtual reality environment from MedicalVR for planning complex lung segmentectomies.

Thirona launches AI software for Cystic Fibrosis

Thirona developed an AI algorithm that revolutionizes cystic fibrosis (CF) care. The new algorithm, coined PRAGMA-AI, allows for fast, automated analysis of CT scans of patients with CF to detect and quantify lung abnormalities related to CF. These quantifications are critical in determining the status of the patient and determine optimal treatment paths but are not feasible to be performed by humans in clinical care. The release of PRAGMA-AI paves the way for large-scale usage in clinical trials and clinical care for better diagnostics, patient monitoring, and treatment planning.

LUMC calculates lung damages COVID-19 patients with AI technology

Healthcare professionals at Leiden University Medical Centre (LUMC) can use artificial intelligence (AI) to quickly and easily calculate whether a corona patient has suffered serious lung damage. They do this by running a CT scan through the AI software CAD4COVID-CT. The software was developed by the company Thirona and is used in the LUMC via Philips Intellispace AI Workflow Suite.

The Canisius Wilhelmina Ziekenhuis in Nijmegen is now using CAD4COVID-CT in their clinical practice!

Our CAD4COVID software will help to assess affected lung tissue in COVID-19 patients. We have worked closely together with CWZ over the past month to integrate the solution in their daily workflow, and are really happy with the result.

Thirona is now compliant with the new Medical Device Regulation

The new EU Medical Device Regulation (MDR) 2017/745, which will come into full effect in May 2021, has a major impact on medical device manufacturers worldwide. Implementation of the new regulations has manufacturers facing challenges due to the stricter rules, limited resources, and lack of clear EU guidance. Therefore, we are especially proud to announce that Thirona successfully implemented the requirements and we are now certified against the new MDR.

Thirona obtains patent for quantitative analysis of Cystic Fibrosis in children

Thirona has obtained an exclusive license on a patent in relation to Cystic Fibrosis (CF),  a rare genetic condition that creates lung abnormalities from a very early age. The patent allows us to develop an AI algorithm that will analyse CT scans to identify even the smallest abnormalities in the lungs, especially early on, ensuring that the right treatment can follow.

Go to Top